Insider · CIK 0001221451
Stephen Rocamboli
Files at ESPR (Esperion Therapeutics, Inc.). First filing -, latest -.
In brief
Stephen Rocamboli files SEC Form 4 as director at ESPR (Esperion Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Stephen Rocamboli has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2025 | ESPR Esperion Therapeutics, Inc. | AGrant or award Common Stock | +33,000 | $0.00 | $0 | 69,261 | Jun 2, 2025 |
| May 29, 2025 | ESPR Esperion Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 2, 2025 |
Questions about Stephen Rocamboli
Answered from the filings on this page, as of the latest one.
Is Stephen Rocamboli buying or selling?
Stephen Rocamboli has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Stephen Rocamboli's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stephen Rocamboli has 0.
Where does Stephen Rocamboli file Form 4?
Stephen Rocamboli has filed Form 4 at ESPR (Esperion Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.